IL188127A - Method of developing a biologically active agent that modulates demyelination disorder, uses thereof and a method of testing the same - Google Patents

Info

Publication number

IL188127A

IL188127A IL188127A IL18812707A IL188127A IL 188127 A IL188127 A IL 188127A IL 188127 A IL188127 A IL 188127A IL 18812707 A IL18812707 A IL 18812707A IL 188127 A IL188127 A IL 188127A

Authority

IL

Israel

Prior art keywords

mice

ifn

cell

protein

expression

Prior art date

2005-06-14

Links

• Espacenet
• Global Dossier
• Discuss

• 208000016192 Demyelinating disease Diseases 0.000 title claims description 144
• 206010012305 Demyelination Diseases 0.000 title claims description 140
• 238000000034 method Methods 0.000 title claims description 118
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 84
• 208000035475 disorder Diseases 0.000 title claims description 40
• 239000013543 active substance Substances 0.000 title claims description 32
• 238000010998 test method Methods 0.000 title claims description 6
• 108090000623 proteins and genes Proteins 0.000 claims description 271
• 210000004248 oligodendroglia Anatomy 0.000 claims description 265
• 210000004027 cell Anatomy 0.000 claims description 235
• 230000014509 gene expression Effects 0.000 claims description 188
• 108010074328 Interferon-gamma Proteins 0.000 claims description 171
• 241001465754 Metazoa Species 0.000 claims description 167
• 108700027336 Suppressor of Cytokine Signaling 1 Proteins 0.000 claims description 147
• 102100024779 Suppressor of cytokine signaling 1 Human genes 0.000 claims description 146
• 210000002472 endoplasmic reticulum Anatomy 0.000 claims description 115
• 102000004169 proteins and genes Human genes 0.000 claims description 114
• 210000003169 central nervous system Anatomy 0.000 claims description 107
• 230000009261 transgenic effect Effects 0.000 claims description 96
• 230000000694 effects Effects 0.000 claims description 90
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 84
• 239000003795 chemical substances by application Substances 0.000 claims description 66
• 230000003902 lesion Effects 0.000 claims description 50
• 210000003050 axon Anatomy 0.000 claims description 48
• 230000001537 neural effect Effects 0.000 claims description 46
• 210000001519 tissue Anatomy 0.000 claims description 42
• 230000037361 pathway Effects 0.000 claims description 41
• 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 claims description 39
• 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 claims description 38
• 125000003729 nucleotide group Chemical group 0.000 claims description 36
• 108020004459 Small interfering RNA Proteins 0.000 claims description 33
• 239000002773 nucleotide Substances 0.000 claims description 32
• 230000001965 increasing effect Effects 0.000 claims description 31
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
• 239000004055 small Interfering RNA Substances 0.000 claims description 30
• 108010033644 N-acylsphingosine galactosyltransferase Proteins 0.000 claims description 28
• 108090000570 Caspase-12 Proteins 0.000 claims description 26
• 102000004066 Caspase-12 Human genes 0.000 claims description 26
• 201000006417 multiple sclerosis Diseases 0.000 claims description 25
• 238000003556 assay Methods 0.000 claims description 24
• 210000004116 schwann cell Anatomy 0.000 claims description 22
• 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 claims description 21
• 108091000080 Phosphotransferase Proteins 0.000 claims description 19
• 238000009396 hybridization Methods 0.000 claims description 19
• 230000001404 mediated effect Effects 0.000 claims description 19
• 230000009467 reduction Effects 0.000 claims description 18
• 102000008070 Interferon-gamma Human genes 0.000 claims description 17
• 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims description 17
• 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims description 17
• 238000009739 binding Methods 0.000 claims description 16
• 230000002596 correlated effect Effects 0.000 claims description 16
• 229960003130 interferon gamma Drugs 0.000 claims description 16
• 210000000653 nervous system Anatomy 0.000 claims description 16
• 210000002569 neuron Anatomy 0.000 claims description 16
• 230000027455 binding Effects 0.000 claims description 14
• 230000006378 damage Effects 0.000 claims description 14
• 102100035917 Peripheral myelin protein 22 Human genes 0.000 claims description 13
• 101710199257 Peripheral myelin protein 22 Proteins 0.000 claims description 13
• 102000055325 Myelin P0 Human genes 0.000 claims description 12
• 108050003852 Myelin protein P0 Proteins 0.000 claims description 12
• 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 claims description 12
• 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 claims description 12
• 108010035430 X-Box Binding Protein 1 Proteins 0.000 claims description 12
• 102100038151 X-box-binding protein 1 Human genes 0.000 claims description 12
• LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 claims description 12
• 239000003550 marker Substances 0.000 claims description 12
• 108010005298 Oligodendrocyte-Myelin Glycoprotein Proteins 0.000 claims description 11
• 102100026746 Oligodendrocyte-myelin glycoprotein Human genes 0.000 claims description 11
• 239000012634 fragment Substances 0.000 claims description 11
• 230000002757 inflammatory effect Effects 0.000 claims description 11
• 230000014621 translational initiation Effects 0.000 claims description 11
• 108010085405 Activating Transcription Factor 6 Proteins 0.000 claims description 10
• 230000011664 signaling Effects 0.000 claims description 10
• 230000005778 DNA damage Effects 0.000 claims description 9
• 231100000277 DNA damage Toxicity 0.000 claims description 9
• 230000007423 decrease Effects 0.000 claims description 9
• 230000012010 growth Effects 0.000 claims description 9
• 230000002401 inhibitory effect Effects 0.000 claims description 9
• 102000020233 phosphotransferase Human genes 0.000 claims description 9
• 239000005557 antagonist Substances 0.000 claims description 8
• 230000001939 inductive effect Effects 0.000 claims description 8
• 239000002502 liposome Substances 0.000 claims description 8
• 239000008194 pharmaceutical composition Substances 0.000 claims description 8
• 208000027418 Wounds and injury Diseases 0.000 claims description 7
• 208000014674 injury Diseases 0.000 claims description 7
• 102000014914 Carrier Proteins Human genes 0.000 claims description 6
• 108010077641 Nogo Proteins Proteins 0.000 claims description 6
• 108010049395 Prokaryotic Initiation Factor-2 Proteins 0.000 claims description 6
• 102000016202 Proteolipids Human genes 0.000 claims description 6
• 108010010974 Proteolipids Proteins 0.000 claims description 6
• 102100029831 Reticulon-4 Human genes 0.000 claims description 6
• 108091008324 binding proteins Proteins 0.000 claims description 6
• 244000052769 pathogen Species 0.000 claims description 6
• 230000001737 promoting effect Effects 0.000 claims description 6
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 5
• 108010044843 Peptide Initiation Factors Proteins 0.000 claims description 5
• 102000005877 Peptide Initiation Factors Human genes 0.000 claims description 5
• SPSGYTWOIGAABK-DQEYMECFSA-N [4-[(2s)-2-acetamido-3-[[(5s)-3-carbamoyl-2-(cyclohexylmethoxy)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-5-yl]amino]-3-oxopropyl]-2-phosphonophenyl]phosphonic acid Chemical group C([C@H](NC(=O)C)C(=O)N[C@@H]1C2=CC(=C(OCC3CCCCC3)C=C2CCCC1)C(N)=O)C1=CC=C(P(O)(O)=O)C(P(O)(O)=O)=C1 SPSGYTWOIGAABK-DQEYMECFSA-N 0.000 claims description 5
• 239000003623 enhancer Substances 0.000 claims description 5
• 229960000367 inositol Drugs 0.000 claims description 5
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 5
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 5
• 230000002459 sustained effect Effects 0.000 claims description 5
• 241000124008 Mammalia Species 0.000 claims description 4
• 101000611644 Mus musculus Protein phosphatase 1 regulatory subunit 15B Proteins 0.000 claims description 4
• 108091034117 Oligonucleotide Proteins 0.000 claims description 4
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 4
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 4
• 102000005569 Protein Phosphatase 1 Human genes 0.000 claims description 4
• 108010059000 Protein Phosphatase 1 Proteins 0.000 claims description 4
• 239000000427 antigen Substances 0.000 claims description 3
• 108091007433 antigens Proteins 0.000 claims description 3
• 102000036639 antigens Human genes 0.000 claims description 3
• 238000003018 immunoassay Methods 0.000 claims description 3
• 230000001717 pathogenic effect Effects 0.000 claims description 3
• 241000288906 Primates Species 0.000 claims description 2
• 241000283984 Rodentia Species 0.000 claims description 2
• 241000700605 Viruses Species 0.000 claims description 2
• 150000002894 organic compounds Chemical class 0.000 claims description 2
• 102000007481 Activating Transcription Factor 6 Human genes 0.000 claims 2
• 239000002771 cell marker Substances 0.000 claims 2
• 108010089429 PERK kinase Proteins 0.000 claims 1
• 239000000074 antisense oligonucleotide Substances 0.000 claims 1
• 238000012230 antisense oligonucleotides Methods 0.000 claims 1
• 239000000539 dimer Substances 0.000 claims 1
• 150000002484 inorganic compounds Chemical class 0.000 claims 1
• 229910010272 inorganic material Inorganic materials 0.000 claims 1
• 241000699670 Mus sp. Species 0.000 description 356
• 102100037850 Interferon gamma Human genes 0.000 description 152
• 235000018102 proteins Nutrition 0.000 description 108
• 201000002491 encephalomyelitis Diseases 0.000 description 98
• 238000011830 transgenic mouse model Methods 0.000 description 97
• 241000699660 Mus musculus Species 0.000 description 90
• 102000047918 Myelin Basic Human genes 0.000 description 76
• 101710107068 Myelin basic protein Proteins 0.000 description 76
• SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 69
• 229960003722 doxycycline Drugs 0.000 description 69
• 210000000278 spinal cord Anatomy 0.000 description 61
• 238000004458 analytical method Methods 0.000 description 53
• 210000004556 brain Anatomy 0.000 description 52
• 210000000877 corpus callosum Anatomy 0.000 description 51
• 239000000523 sample Substances 0.000 description 51
• 238000012744 immunostaining Methods 0.000 description 49
• 238000003753 real-time PCR Methods 0.000 description 49
• 239000000047 product Substances 0.000 description 48
• 108010083674 Myelin Proteins Proteins 0.000 description 43
• 108700019146 Transgenes Proteins 0.000 description 42
• 201000010099 disease Diseases 0.000 description 42
• 210000005230 lumbar spinal cord Anatomy 0.000 description 41
• 108020004999 messenger RNA Proteins 0.000 description 39
• DSRJIHMZAQEUJV-UHFFFAOYSA-N Cuprizon Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 36
• 102000006386 Myelin Proteins Human genes 0.000 description 36
• 230000000692 anti-sense effect Effects 0.000 description 33
• 238000012360 testing method Methods 0.000 description 33
• 230000004913 activation Effects 0.000 description 31
• 239000013598 vector Substances 0.000 description 31
• 210000005012 myelin Anatomy 0.000 description 30
• 102000040430 polynucleotide Human genes 0.000 description 27
• 108091033319 polynucleotide Proteins 0.000 description 27
• 239000002157 polynucleotide Substances 0.000 description 27
• 230000023105 myelination Effects 0.000 description 26
• 238000001262 western blot Methods 0.000 description 25
• 230000013011 mating Effects 0.000 description 24
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
• 241000699666 Mus <mouse, genus> Species 0.000 description 22
• 108020004414 DNA Proteins 0.000 description 21
• 210000000130 stem cell Anatomy 0.000 description 21
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 20
• 102100038045 Eukaryotic translation initiation factor 2A Human genes 0.000 description 20
• 101710092068 Eukaryotic translation initiation factor 2A Proteins 0.000 description 20
• 230000006907 apoptotic process Effects 0.000 description 19
• 238000000338 in vitro Methods 0.000 description 19
• 230000026731 phosphorylation Effects 0.000 description 19
• 238000006366 phosphorylation reaction Methods 0.000 description 19
• 230000001105 regulatory effect Effects 0.000 description 18
• 238000011282 treatment Methods 0.000 description 18
• 238000006243 chemical reaction Methods 0.000 description 16
• 238000002372 labelling Methods 0.000 description 16
• 230000008569 process Effects 0.000 description 16
• 102000004127 Cytokines Human genes 0.000 description 15
• 108090000695 Cytokines Proteins 0.000 description 15
• 102000004190 Enzymes Human genes 0.000 description 15
• 108090000790 Enzymes Proteins 0.000 description 15
• 210000001744 T-lymphocyte Anatomy 0.000 description 15
• 238000001514 detection method Methods 0.000 description 15
• 230000006698 induction Effects 0.000 description 15
• 230000008595 infiltration Effects 0.000 description 15
• 238000001764 infiltration Methods 0.000 description 15
• 102000039446 nucleic acids Human genes 0.000 description 15
• 108020004707 nucleic acids Proteins 0.000 description 15
• 150000007523 nucleic acids Chemical class 0.000 description 15
• 102000003952 Caspase 3 Human genes 0.000 description 14
• 108090000397 Caspase 3 Proteins 0.000 description 14
• 238000010171 animal model Methods 0.000 description 14
• 230000008045 co-localization Effects 0.000 description 14
• 230000000875 corresponding effect Effects 0.000 description 14
• 238000003752 polymerase chain reaction Methods 0.000 description 14
• 238000011084 recovery Methods 0.000 description 14
• 230000002829 reductive effect Effects 0.000 description 14
• 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 description 13
• 101710132484 Cytokine-inducible SH2-containing protein Proteins 0.000 description 13
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 13
• 238000011161 development Methods 0.000 description 13
• 230000018109 developmental process Effects 0.000 description 13
• 238000005516 engineering process Methods 0.000 description 13
• 210000001428 peripheral nervous system Anatomy 0.000 description 13
• 238000010186 staining Methods 0.000 description 13
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 12
• 206010033799 Paralysis Diseases 0.000 description 12
• 208000007542 Paresis Diseases 0.000 description 12
• 230000003247 decreasing effect Effects 0.000 description 12
• 230000003210 demyelinating effect Effects 0.000 description 12
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
• 239000002953 phosphate buffered saline Substances 0.000 description 12
• 108010065805 Interleukin-12 Proteins 0.000 description 11
• 102000013462 Interleukin-12 Human genes 0.000 description 11
• 108010002350 Interleukin-2 Proteins 0.000 description 11
• 102000000588 Interleukin-2 Human genes 0.000 description 11
• 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 11
• 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 11
• 238000002474 experimental method Methods 0.000 description 11
• 230000009368 gene silencing by RNA Effects 0.000 description 11
• 239000012528 membrane Substances 0.000 description 11
• 230000035772 mutation Effects 0.000 description 11
• 210000003007 myelin sheath Anatomy 0.000 description 11
• 229920001184 polypeptide Polymers 0.000 description 11
• 102000004196 processed proteins & peptides Human genes 0.000 description 11
• 230000001681 protective effect Effects 0.000 description 11
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 10
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 10
• -1 IL- 12 Proteins 0.000 description 10
• 108091030071 RNAI Proteins 0.000 description 10
• 206010044565 Tremor Diseases 0.000 description 10
• 210000001638 cerebellum Anatomy 0.000 description 10
• 230000002939 deleterious effect Effects 0.000 description 10
• 230000004069 differentiation Effects 0.000 description 10
• 239000000284 extract Substances 0.000 description 10
• 210000003141 lower extremity Anatomy 0.000 description 10
• 239000002609 medium Substances 0.000 description 10
• 239000000203 mixture Substances 0.000 description 10
• 206010003591 Ataxia Diseases 0.000 description 9
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• 102000055324 Myelin Proteolipid Human genes 0.000 description 9
• 241000700159 Rattus Species 0.000 description 9
• 230000005856 abnormality Effects 0.000 description 9
• 230000003321 amplification Effects 0.000 description 9
• 210000001130 astrocyte Anatomy 0.000 description 9
• 230000008859 change Effects 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 150000001875 compounds Chemical class 0.000 description 9
• 238000012217 deletion Methods 0.000 description 9
• 230000037430 deletion Effects 0.000 description 9
• 230000001419 dependent effect Effects 0.000 description 9
• 210000001671 embryonic stem cell Anatomy 0.000 description 9
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
• 229910052739 hydrogen Inorganic materials 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 238000003199 nucleic acid amplification method Methods 0.000 description 9
• 230000008506 pathogenesis Effects 0.000 description 9
• 102100023583 Cyclic AMP-dependent transcription factor ATF-6 alpha Human genes 0.000 description 8
• 108700021862 Myelin Proteolipid Proteins 0.000 description 8
• 229930040373 Paraformaldehyde Natural products 0.000 description 8
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
• 229940024606 amino acid Drugs 0.000 description 8
• 235000001014 amino acid Nutrition 0.000 description 8
• 150000001413 amino acids Chemical class 0.000 description 8
• 230000009977 dual effect Effects 0.000 description 8
• 239000012091 fetal bovine serum Substances 0.000 description 8
• 230000002518 glial effect Effects 0.000 description 8
• 230000005937 nuclear translocation Effects 0.000 description 8
• 210000004940 nucleus Anatomy 0.000 description 8
• 229920002866 paraformaldehyde Polymers 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 230000016914 response to endoplasmic reticulum stress Effects 0.000 description 8
• 229950003937 tolonium Drugs 0.000 description 8
• HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 8
• 230000014616 translation Effects 0.000 description 8
• 229920004890 Triton X-100 Polymers 0.000 description 7
• 239000013504 Triton X-100 Substances 0.000 description 7
• 230000007844 axonal damage Effects 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 230000001413 cellular effect Effects 0.000 description 7
• 230000001120 cytoprotective effect Effects 0.000 description 7
• 238000010790 dilution Methods 0.000 description 7
• 239000012895 dilution Substances 0.000 description 7
• 239000013604 expression vector Substances 0.000 description 7
• 239000000835 fiber Substances 0.000 description 7
• 238000001114 immunoprecipitation Methods 0.000 description 7
• 239000006166 lysate Substances 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 230000003938 response to stress Effects 0.000 description 7
• 230000019491 signal transduction Effects 0.000 description 7
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 6
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 6
• 238000011740 C57BL/6 mouse Methods 0.000 description 6
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
• 102000003814 Interleukin-10 Human genes 0.000 description 6
• 108090000174 Interleukin-10 Proteins 0.000 description 6
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 6
• 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 102100040247 Tumor necrosis factor Human genes 0.000 description 6
• 210000005056 cell body Anatomy 0.000 description 6
• 238000003776 cleavage reaction Methods 0.000 description 6
• 239000002299 complementary DNA Substances 0.000 description 6
• 230000034994 death Effects 0.000 description 6
• 238000001493 electron microscopy Methods 0.000 description 6
• 238000011156 evaluation Methods 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 229930195712 glutamate Natural products 0.000 description 6
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 230000000266 injurious effect Effects 0.000 description 6
• 210000004498 neuroglial cell Anatomy 0.000 description 6
• 230000002018 overexpression Effects 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 230000004043 responsiveness Effects 0.000 description 6
• 230000007017 scission Effects 0.000 description 6
• 230000009211 stress pathway Effects 0.000 description 6
• 210000001364 upper extremity Anatomy 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• 102000013691 Interleukin-17 Human genes 0.000 description 5
• 108050003558 Interleukin-17 Proteins 0.000 description 5
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
• 238000000636 Northern blotting Methods 0.000 description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 description 5
• 239000000556 agonist Substances 0.000 description 5
• 230000004075 alteration Effects 0.000 description 5
• 230000001640 apoptogenic effect Effects 0.000 description 5
• 230000003376 axonal effect Effects 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 210000000170 cell membrane Anatomy 0.000 description 5
• 210000000805 cytoplasm Anatomy 0.000 description 5
• 230000001934 delay Effects 0.000 description 5
• 230000003111 delayed effect Effects 0.000 description 5
• 230000003292 diminished effect Effects 0.000 description 5
• 238000009826 distribution Methods 0.000 description 5
• 230000013632 homeostatic process Effects 0.000 description 5
• 230000028993 immune response Effects 0.000 description 5
• 238000002991 immunohistochemical analysis Methods 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 210000001161 mammalian embryo Anatomy 0.000 description 5
• 210000005036 nerve Anatomy 0.000 description 5
• 210000005155 neural progenitor cell Anatomy 0.000 description 5
• 108010091047 neurofilament protein H Proteins 0.000 description 5
• 210000000535 oligodendrocyte precursor cell Anatomy 0.000 description 5
• 230000002516 postimmunization Effects 0.000 description 5
• 239000002243 precursor Substances 0.000 description 5
• 238000001243 protein synthesis Methods 0.000 description 5
• 238000010839 reverse transcription Methods 0.000 description 5
• LCOIAYJMPKXARU-VAWYXSNFSA-N salubrinal Chemical compound C=1C=CC2=CC=CN=C2C=1NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\C1=CC=CC=C1 LCOIAYJMPKXARU-VAWYXSNFSA-N 0.000 description 5
• 239000007787 solid Substances 0.000 description 5
• 210000000952 spleen Anatomy 0.000 description 5
• 230000004960 subcellular localization Effects 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
• 238000001890 transfection Methods 0.000 description 5
• 230000004906 unfolded protein response Effects 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 108010076667 Caspases Proteins 0.000 description 4
• 102000011727 Caspases Human genes 0.000 description 4
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 4
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 4
• 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 4
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 4
• 101150112743 HSPA5 gene Proteins 0.000 description 4
• 101000693970 Homo sapiens Scavenger receptor class A member 3 Proteins 0.000 description 4
• 108010002616 Interleukin-5 Proteins 0.000 description 4
• 102000000743 Interleukin-5 Human genes 0.000 description 4
• 108091054437 MHC class I family Proteins 0.000 description 4
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 4
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 4
• 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 4
• 102100027192 Scavenger receptor class A member 3 Human genes 0.000 description 4
• 238000009825 accumulation Methods 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 230000003542 behavioural effect Effects 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 210000005013 brain tissue Anatomy 0.000 description 4
• 238000000423 cell based assay Methods 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• 230000005754 cellular signaling Effects 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 4
• 230000001627 detrimental effect Effects 0.000 description 4
• 235000005911 diet Nutrition 0.000 description 4
• 230000037213 diet Effects 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 210000003414 extremity Anatomy 0.000 description 4
• 238000001415 gene therapy Methods 0.000 description 4
• 101150028578 grp78 gene Proteins 0.000 description 4
• 230000009931 harmful effect Effects 0.000 description 4
• 239000001257 hydrogen Substances 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 208000036546 leukodystrophy Diseases 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 230000004777 loss-of-function mutation Effects 0.000 description 4
• 210000000274 microglia Anatomy 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 230000028266 oligodendrocyte apoptotic process Effects 0.000 description 4
• 210000000056 organ Anatomy 0.000 description 4
• 210000003463 organelle Anatomy 0.000 description 4
• CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 4
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 4
• 210000004129 prosencephalon Anatomy 0.000 description 4
• 230000002633 protecting effect Effects 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 229920005989 resin Polymers 0.000 description 4
• 239000011347 resin Substances 0.000 description 4
• 230000001177 retroviral effect Effects 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 210000004895 subcellular structure Anatomy 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 230000002103 transcriptional effect Effects 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
• NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 3
• 108090000994 Catalytic RNA Proteins 0.000 description 3
• 102000053642 Catalytic RNA Human genes 0.000 description 3
• 108091026890 Coding region Proteins 0.000 description 3
• 230000004568 DNA-binding Effects 0.000 description 3
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 102100035678 Interferon gamma receptor 1 Human genes 0.000 description 3
• 102000043129 MHC class I family Human genes 0.000 description 3
• 238000000134 MTT assay Methods 0.000 description 3
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 239000000020 Nitrocellulose Substances 0.000 description 3
• 108010081690 Pertussis Toxin Proteins 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• 108010076504 Protein Sorting Signals Proteins 0.000 description 3
• 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
• 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 238000012288 TUNEL assay Methods 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 230000002776 aggregation Effects 0.000 description 3
• 238000004220 aggregation Methods 0.000 description 3
• 208000026935 allergic disease Diseases 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 239000012472 biological sample Substances 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 230000000052 comparative effect Effects 0.000 description 3
• 230000006735 deficit Effects 0.000 description 3
• 239000003814 drug Substances 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 208000010726 hind limb paralysis Diseases 0.000 description 3
• 230000009610 hypersensitivity Effects 0.000 description 3
• 230000002055 immunohistochemical effect Effects 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 210000004969 inflammatory cell Anatomy 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 230000028709 inflammatory response Effects 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 239000007928 intraperitoneal injection Substances 0.000 description 3
• 238000011835 investigation Methods 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 210000002540 macrophage Anatomy 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 239000012120 mounting media Substances 0.000 description 3
• 229920001220 nitrocellulos Polymers 0.000 description 3
• 230000003287 optical effect Effects 0.000 description 3
• 230000002093 peripheral effect Effects 0.000 description 3
• 210000001778 pluripotent stem cell Anatomy 0.000 description 3
• 230000004481 post-translational protein modification Effects 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 238000002731 protein assay Methods 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 230000008929 regeneration Effects 0.000 description 3
• 238000011069 regeneration method Methods 0.000 description 3
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
• 230000008439 repair process Effects 0.000 description 3
• 108091092562 ribozyme Proteins 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 239000007929 subcutaneous injection Substances 0.000 description 3
• 238000010254 subcutaneous injection Methods 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000000451 tissue damage Effects 0.000 description 3
• 231100000827 tissue damage Toxicity 0.000 description 3
• 239000003440 toxic substance Substances 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 230000005945 translocation Effects 0.000 description 3
• 230000009452 underexpressoin Effects 0.000 description 3
• 230000035899 viability Effects 0.000 description 3
• 230000009385 viral infection Effects 0.000 description 3
• 210000004885 white matter Anatomy 0.000 description 3
• JBFQOLHAGBKPTP-NZATWWQASA-N (2s)-2-[[(2s)-4-carboxy-2-[[3-carboxy-2-[[(2s)-2,6-diaminohexanoyl]amino]propanoyl]amino]butanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)C(CC(O)=O)NC(=O)[C@@H](N)CCCCN JBFQOLHAGBKPTP-NZATWWQASA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• 102000007469 Actins Human genes 0.000 description 2
• 108010085238 Actins Proteins 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• 208000011403 Alexander disease Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
• 208000000412 Avitaminosis Diseases 0.000 description 2
• 208000022526 Canavan disease Diseases 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 241000700198 Cavia Species 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 2
• 108010077544 Chromatin Proteins 0.000 description 2
• 208000010200 Cockayne syndrome Diseases 0.000 description 2
• 206010010904 Convulsion Diseases 0.000 description 2
• 238000000116 DAPI staining Methods 0.000 description 2
• 102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 102000001301 EGF receptor Human genes 0.000 description 2
• 108060006698 EGF receptor Proteins 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 238000012286 ELISA Assay Methods 0.000 description 2
• 108700005000 Glial Fibrillary Acidic Proteins 0.000 description 2
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• 208000026350 Inborn Genetic disease Diseases 0.000 description 2
• 102100034343 Integrase Human genes 0.000 description 2
• 102000004310 Ion Channels Human genes 0.000 description 2
• 231100000002 MTT assay Toxicity 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 208000001089 Multiple system atrophy Diseases 0.000 description 2
• 101000918632 Mus musculus DNA damage-inducible transcript 3 protein Proteins 0.000 description 2
• 102100026784 Myelin proteolipid protein Human genes 0.000 description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
• 108700020796 Oncogene Proteins 0.000 description 2
• 241000282579 Pan Species 0.000 description 2
• 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 2
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
• 208000005587 Refsum Disease Diseases 0.000 description 2
• 108010083644 Ribonucleases Proteins 0.000 description 2
• 102000006382 Ribonucleases Human genes 0.000 description 2
• 108091027967 Small hairpin RNA Proteins 0.000 description 2
• 238000000692 Student's t-test Methods 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 241000282887 Suidae Species 0.000 description 2
• 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
• 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 2
• 239000004098 Tetracycline Substances 0.000 description 2
• 206010043994 Tonic convulsion Diseases 0.000 description 2
• 108010057666 Transcription Factor CHOP Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 201000004810 Vascular dementia Diseases 0.000 description 2
• 206010047627 Vitamin deficiencies Diseases 0.000 description 2
• 201000004525 Zellweger Syndrome Diseases 0.000 description 2
• 208000036813 Zellweger spectrum disease Diseases 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 208000030597 adult Refsum disease Diseases 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 230000006472 autoimmune response Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 2
• 229940098773 bovine serum albumin Drugs 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 235000011089 carbon dioxide Nutrition 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 210000003855 cell nucleus Anatomy 0.000 description 2
• 238000002659 cell therapy Methods 0.000 description 2
• 208000009885 central pontine myelinolysis Diseases 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 210000003483 chromatin Anatomy 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 230000030609 dephosphorylation Effects 0.000 description 2
• 238000006209 dephosphorylation reaction Methods 0.000 description 2
• 238000009795 derivation Methods 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 230000007783 downstream signaling Effects 0.000 description 2
• 229940079593 drug Drugs 0.000 description 2
• 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 description 2
• 230000005014 ectopic expression Effects 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 238000000635 electron micrograph Methods 0.000 description 2
• 238000010218 electron microscopic analysis Methods 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 description 2
• 210000002242 embryoid body Anatomy 0.000 description 2
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
• 229960005542 ethidium bromide Drugs 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 208000016361 genetic disease Diseases 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 210000001308 heart ventricle Anatomy 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 239000012133 immunoprecipitate Substances 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 230000029226 lipidation Effects 0.000 description 2
• 108010089256 lysyl-aspartyl-glutamyl-leucine Proteins 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 230000002025 microglial effect Effects 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 230000000877 morphologic effect Effects 0.000 description 2
• 230000004660 morphological change Effects 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 230000030648 nucleus localization Effects 0.000 description 2
• 210000000287 oocyte Anatomy 0.000 description 2
• 230000001590 oxidative effect Effects 0.000 description 2
• 208000021090 palsy Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 108010091212 pepstatin Proteins 0.000 description 2
• FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• 238000005375 photometry Methods 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 231100000614 poison Toxicity 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 238000004321 preservation Methods 0.000 description 2
• 108020003519 protein disulfide isomerase Proteins 0.000 description 2
• 230000012846 protein folding Effects 0.000 description 2
• 230000005892 protein maturation Effects 0.000 description 2
• 230000009145 protein modification Effects 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 210000003497 sciatic nerve Anatomy 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 239000011669 selenium Substances 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 230000000405 serological effect Effects 0.000 description 2
• 208000020431 spinal cord injury Diseases 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 230000009221 stress response pathway Effects 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 229960002180 tetracycline Drugs 0.000 description 2
• 229930101283 tetracycline Natural products 0.000 description 2
• 235000019364 tetracycline Nutrition 0.000 description 2
• 150000003522 tetracyclines Chemical class 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
• 108010022794 2',3'-Cyclic-Nucleotide Phosphodiesterases Proteins 0.000 description 1
• 102100040458 2',3'-cyclic-nucleotide 3'-phosphodiesterase Human genes 0.000 description 1
• 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
• KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
• QEVHRUUCFGRFIF-UHFFFAOYSA-N 6,18-dimethoxy-17-[oxo-(3,4,5-trimethoxyphenyl)methoxy]-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid methyl ester Chemical compound C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
• 108091006112 ATPases Proteins 0.000 description 1
• 101800000263 Acidic protein Proteins 0.000 description 1
• 108010045938 Adaptor Protein Complex gamma Subunits Proteins 0.000 description 1
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 241000428352 Amma Species 0.000 description 1
• 108010070255 Aspartate-ammonia ligase Proteins 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 101150003242 Bbc3 gene Proteins 0.000 description 1
• 102100021572 Bcl-2-binding component 3, isoforms 1/2 Human genes 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
• 102000009122 CCAAT-Enhancer-Binding Proteins Human genes 0.000 description 1
• 108010048401 CCAAT-Enhancer-Binding Proteins Proteins 0.000 description 1
• 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 1
• 101710134031 CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
• 102100021868 Calnexin Human genes 0.000 description 1
• 108010056891 Calnexin Proteins 0.000 description 1
• 102100029968 Calreticulin Human genes 0.000 description 1
• 108090000549 Calreticulin Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 206010010947 Coordination abnormal Diseases 0.000 description 1
• 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
• DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 102000004594 DNA Polymerase I Human genes 0.000 description 1
• 108010017826 DNA Polymerase I Proteins 0.000 description 1
• 239000012625 DNA intercalator Substances 0.000 description 1
• 241000450599 DNA viruses Species 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 101100451497 Dictyostelium discoideum hspB gene Proteins 0.000 description 1
• 101100533283 Dictyostelium discoideum serp gene Proteins 0.000 description 1
• SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
• 102100038002 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit STT3A Human genes 0.000 description 1
• 101710133440 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit STT3A Proteins 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 102100039328 Endoplasmin Human genes 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 description 1
• 101150022862 HSC70 gene Proteins 0.000 description 1
• 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 1
• 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 101000971203 Homo sapiens Bcl-2-binding component 3, isoforms 1/2 Proteins 0.000 description 1
• 101000971209 Homo sapiens Bcl-2-binding component 3, isoforms 3/4 Proteins 0.000 description 1
• 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 1
• 101000855520 Homo sapiens Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
• 101000616112 Homo sapiens Stress-associated endoplasmic reticulum protein 1 Proteins 0.000 description 1
• 101000629921 Homo sapiens Translocon-associated protein subunit delta Proteins 0.000 description 1
• 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 102100023915 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 208000028226 Krabbe disease Diseases 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
• 101150028955 MBP gene Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010006519 Molecular Chaperones Proteins 0.000 description 1
• 102000005431 Molecular Chaperones Human genes 0.000 description 1
• 208000034486 Multi-organ failure Diseases 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101000983517 Mus musculus Caspase-12 Proteins 0.000 description 1
• 101100440286 Mus musculus Cntrl gene Proteins 0.000 description 1
• 101100444898 Mus musculus Egr1 gene Proteins 0.000 description 1
• 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
• 206010067482 No adverse event Diseases 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 108010038807 Oligopeptides Proteins 0.000 description 1
• 102000015636 Oligopeptides Human genes 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 238000009004 PCR Kit Methods 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 239000002033 PVDF binder Substances 0.000 description 1
• 241000282520 Papio Species 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
• 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 208000016012 Phenotypic abnormality Diseases 0.000 description 1
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
• WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 101710132807 Protein P5 Proteins 0.000 description 1
• 238000001190 Q-PCR Methods 0.000 description 1
• 239000012083 RIPA buffer Substances 0.000 description 1
• 108020004518 RNA Probes Proteins 0.000 description 1
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
• 239000003391 RNA probe Substances 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 101001044455 Rattus norvegicus Interferon gamma Proteins 0.000 description 1
• 101100353123 Rattus norvegicus Ppp1r15a gene Proteins 0.000 description 1
• 206010038997 Retroviral infections Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
• SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 description 1
• 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
• 241000320134 Sacura Species 0.000 description 1
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
• 206010040026 Sensory disturbance Diseases 0.000 description 1
• 102100027287 Serpin H1 Human genes 0.000 description 1
• 108050008290 Serpin H1 Proteins 0.000 description 1
• 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
• 102100030510 Stanniocalcin-2 Human genes 0.000 description 1
• 101710142154 Stanniocalcin-2 Proteins 0.000 description 1
• 102100021813 Stress-associated endoplasmic reticulum protein 1 Human genes 0.000 description 1
• 101710151717 Stress-related protein Proteins 0.000 description 1
• 101710137500 T7 RNA polymerase Proteins 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 102100026226 Translocon-associated protein subunit delta Human genes 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
• 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
• VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 1
• COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
• 108010046334 Urease Proteins 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 206010047571 Visual impairment Diseases 0.000 description 1
• 208000037919 acquired disease Diseases 0.000 description 1
• DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
• 150000001251 acridines Chemical class 0.000 description 1
• 229940023020 acriflavine Drugs 0.000 description 1
• 210000001642 activated microglia Anatomy 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 230000019711 apoptosis in response to endoplasmic reticulum stress Effects 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 239000005441 aurora Substances 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 230000004094 calcium homeostasis Effects 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 230000009744 cell cycle exit Effects 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 229960003677 chloroquine Drugs 0.000 description 1
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
• 230000019113 chromatin silencing Effects 0.000 description 1
• ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 230000010250 cytokine signaling pathway Effects 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
• 230000000254 damaging effect Effects 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000010217 densitometric analysis Methods 0.000 description 1
• 239000005547 deoxyribonucleotide Substances 0.000 description 1
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
• 230000000994 depressogenic effect Effects 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
• SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 238000012137 double-staining Methods 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 238000011977 dual antiplatelet therapy Methods 0.000 description 1
• 108010037623 eIF-2 Kinase Proteins 0.000 description 1
• 102000010982 eIF-2 Kinase Human genes 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 239000003822 epoxy resin Substances 0.000 description 1
• 230000006592 excitoxicity Effects 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 230000003619 fibrillary effect Effects 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 239000012520 frozen sample Substances 0.000 description 1
• 238000011207 functional examination Methods 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000003500 gene array Methods 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000010363 gene targeting Methods 0.000 description 1
• 238000003205 genotyping method Methods 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
• 108010017007 glucose-regulated proteins Proteins 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 150000003278 haem Chemical class 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 230000000971 hippocampal effect Effects 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 238000010562 histological examination Methods 0.000 description 1
• 230000003118 histopathologic effect Effects 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 238000013388 immunohistochemistry analysis Methods 0.000 description 1
• 239000003547 immunosorbent Substances 0.000 description 1
• 230000008676 import Effects 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000003017 in situ immunoassay Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 208000028756 lack of coordination Diseases 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000007762 localization of cell Effects 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 238000010208 microarray analysis Methods 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 230000006724 microglial activation Effects 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 210000001700 mitochondrial membrane Anatomy 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
• UPBAOYRENQEPJO-UHFFFAOYSA-N n-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide Chemical compound CN1C=C(NC=O)C=C1C(=O)NC1=CN(C)C(C(=O)NC2=CN(C)C(C(=O)NCCC(N)=N)=C2)=C1 UPBAOYRENQEPJO-UHFFFAOYSA-N 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 210000003061 neural cell Anatomy 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 235000021590 normal diet Nutrition 0.000 description 1
• 238000012758 nuclear staining Methods 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 238000002966 oligonucleotide array Methods 0.000 description 1
• 239000012285 osmium tetroxide Substances 0.000 description 1
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
• 210000004681 ovum Anatomy 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 108010052258 oxygen-regulated proteins Proteins 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 108091005981 phosphorylated proteins Proteins 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229920000647 polyepoxide Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 125000004424 polypyridyl Polymers 0.000 description 1
• 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000007542 postnatal development Effects 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 229960000286 proflavine Drugs 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 230000004845 protein aggregation Effects 0.000 description 1
• 230000026447 protein localization Effects 0.000 description 1
• 238000005086 pumping Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000012207 quantitative assay Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000003127 radioimmunoassay Methods 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 239000002684 recombinant hormone Substances 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 230000007441 retrograde transport Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 108010052833 ribonuclease HI Proteins 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 125000002652 ribonucleotide group Chemical group 0.000 description 1
• 108020004418 ribosomal RNA Proteins 0.000 description 1
• 229910052707 ruthenium Inorganic materials 0.000 description 1
• 230000009291 secondary effect Effects 0.000 description 1
• 229910052711 selenium Inorganic materials 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000011895 specific detection Methods 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 108010042747 stallimycin Proteins 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 239000010902 straw Substances 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
• 230000000542 thalamic effect Effects 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 210000003014 totipotent stem cell Anatomy 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 231100000167 toxic agent Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 238000012033 transcriptional gene silencing Methods 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 238000012250 transgenic expression Methods 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• 230000022860 translational attenuation Effects 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
• 229950004616 tribromoethanol Drugs 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
• 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
• 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 108020005087 unfolded proteins Proteins 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 230000009750 upstream signaling Effects 0.000 description 1
• 208000029257 vision disease Diseases 0.000 description 1
• 230000004393 visual impairment Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1